About Dimerix

Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using our innovative receptor technology to identify and develop drugs in areas with an unmet need.

Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with Kidney Disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.

Dimerix comprises 2 distinct entities:

  • Dimerix Limited (ASX:DXB)
  • Dimerix Biosciences Pty Ltd (a wholly owned subsidiary of Dimerix Limited)

The Dimerix team has extensive experience in the development and commercialisation of pharmaceutical products in the global marketplace.

Capabilities:

  • Opportunity assessment based on indication, patient need, competition, pharmacological properties, regulatory environment, intellectual property positioning and commercial opportunity
  • Integrated drug discovery from target validation through to understanding structure activity relationships and interpreting mechanism of action
  • World class expertise in GPCR (receptor) heteromerization and associated pharmacology
  • Development of Chemistry, Manufacturing and Controls (CMC) package, including manufacturing scale-up to GMP Commercial Manufacturing Organisations
  • Pre-clinical development of drug candidates to support safety and toxicology assessment
  • Efficient and effective clinical program development through to regulatory submission
  • Material preparation and presentation for regulatory meetings and submissions

Corporate History

Dimerix Bioscience was established as a private company in 2004, based on technology developed at the University of Western Australia, the Receptor-Heteromer Investigation Technology (Receptor-HIT). Dimerix Bioscience went through multiple funding rounds through to mid-2014 when financing was secured for the lead program, DMX-200.

Dimerix Bioscience underwent conversion to a public unlisted company in June 2014 and in July 2015 became a wholly owned subsidiary of Sun Biomedical Limited through a reverse takeover. In November 2015, Sun Biomedical’s name was changed to Dimerix Limited, and now trades under the ASX code: DXB.

Management Team and Board

The Management and Board of Dimerix are experienced biopharmaceutical professionals with the skills and passion to advance new therapeutics though the development and commercialisation pipeline.